New treatment for newly diagnosed glioblastoma patients

Delivery of D2C7-IT and 2141-V11 Combination Immunotherapy in Residual Disease for Adult Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma and Perilymphatic Subcutaneous Injections of 2141-V11

This study is testing a new treatment for people with newly diagnosed glioblastoma to see if it can help manage leftover cancer after surgery and work well with standard radiation therapy.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Duke University (Academic / other)
• Drugs / interventions: radiation
• Locations: 1 site (Durham, North Carolina)
• Trial ID: NCT05734560 on ClinicalTrials.gov

What this trial studies

This clinical trial evaluates the safety and efficacy of two investigational compounds, D2C7-immunotoxin (IT) and 2141-V11, in patients with newly diagnosed glioblastoma. Participants will receive a single intracerebral infusion of D2C7-IT and 2141-V11, followed by subcutaneous injections of 2141-V11 around the lymph nodes. The study aims to assess the treatment's effectiveness in managing residual disease after surgery and its integration with standard radiation therapy. Approximately 50 participants will be enrolled to determine the optimal treatment regimen and monitor for potential side effects.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with newly diagnosed supratentorial glioblastoma that is MGMT unmethylated and has residual disease after standard treatment.

Not a fit: Patients with glioblastoma that is not MGMT unmethylated or those who have not completed standard radiation therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could improve outcomes for patients with newly diagnosed glioblastoma by effectively targeting residual tumor cells.

How similar studies have performed: Other studies have shown promise with similar investigational approaches, but this specific combination is novel.

Eligibility criteria

Inclusion Criteria:

1. Age ≥ 18 years of age at the time of entry into the study
2. Newly diagnosed supratentorial GBM, WHO grade 4, IDH wildtype, MGMT unmethylated (high grade glioma with molecular features of GBM will be eligible under WHO 4 malignant glioma) with residual radiographic non-contrast enhancing disease on the post-2 cycles of adjuvant TMZ MRI amenable to catheter placement. The residual radiographic contrast enhancing disease is ≤ 3 cm in maximal diameter in any plane.
3. Patient must have completed standard of care radiation therapy (typically 59.4-60 Gy over approximately 6 weeks duration if under 65 years old and a minimum of 40 Gy over 3 weeks duration if 65 years or older) in combination with TMZ and 2 cycles of post-radiation, adjuvant TMZ. For patients known to be MGMT promoter unmethylated prior to start of radiation therapy, patients are not mandated to have received TMZ in combination to radiation therapy prior to participating in this trial.
4. Karnofsky Performance Score (KPS) \> 70%
5. Able to undergo brain MRI wiht and without contrast
6. Hemoglobin ≥ 9 g/dl prior to catheter placement
7. Platelet count ≥ 100,000/µL unsupported. Because of risks of intracranial hemorrhage with catheter placement, platelet count ≥ 125,000/µl is required for the patient to undergo biopsy and catheter insertion, which can be attained with the help of platelet transfusion
8. Neutrophil count ≥ 1000 prior to catheter placement
9. Creatinine ≤ 1.5 x normal range prior to catheter placement
10. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) prior to catheter placement (Exception: Participant has known or suspected Gilbert's Syndrome for which additional lab testing of direct and/or indirect bilirubin supports this diagnosis. In these instances, a total bilirubin of ≤ 3.0 x ULN is acceptable.)
11. AST/ALT ≤ 2.5 x ULN
12. PT and PTT ≤ 1.2 x normal prior to biopsy. Patients with prior history of thrombosis/embolism are allowed to be on anticoagulation, understanding that anticoagulation will be held in the perioperative period per the neurosurgical team's recommendations. Low molecular weight heparin (LMWH) is preferred. If a patient is on warfarin, the international normalized ratio (INR) is to be obtained and value should be below 2.0 prior to biopsy.
13. Patient or partner(s) meets one of the following criteria:

    1. Non-childbearing potential (i.e. not sexually active, physiologically incapable of becoming pregnant, including any person who is post-menopausal or surgically sterile, or any person who has had a vasectomy). Surgically sterile people are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Postmenopausal for purposes of this study is defined as 1 year without menses.; or
    2. Childbearing potential and agrees to use one of the following methods of birth control: approved hormonal contraceptives (e.g. birth control pills, patches, implants, or infusions), an intrauterine device, or a barrier method of contraception (e.g. a condom or diaphragm) used with spermicide
14. A signed ICF approved by the IRB will be required for patient enrollment into the study. Patients must be able to read and understand the informed consent document and must sign the informed consent indicating that they are aware of the investigational nature of this study

Exclusion Criteria:

1. Patients who are pregnant or breast-feeding/chestfeeding
2. Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate
3. Patients with severe, active comorbidity, defined as follows:

   1. Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (Tmax \> 99.5°F/37.5°C)
   2. Patients with known immunosuppressive disease or known human immunodeficiency virus infection
   3. Patients with unstable or severe medical conditions such as severe heart disease (New York Heart Association Class 3 or 4)
   4. Patients with known lung (forced expiratory volume in the first second of expiration (FEV1) \< 50%) disease
   5. Patients with uncontrolled diabetes mellitus
   6. Patients with albumin allergy
   7. Patients with known HIV or Hepatitis C positive status
   8. Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy
4. Patients who previously received other therapeutic interventions for newly diagnosed GBM with the exception of surgical resection and standard of care concomitant radiation therapy and TMZ and 2 cycles of post-radiation, adjuvant TMZ for their brain tumor
5. Patients who have received concomitant radiation therapy and TMZ ≤ 11 weeks prior to start of D2C7-IT CED infusion
6. Patients with evidence of tumor in the brainstem, cerebellum, or spinal cord, radiological evidence of (actively growing) multifocal disease, tumor crossing the midline, extensive subependymal disease, or leptomeningeal disease
7. Patients on greater than 4 mg per day of dexamethasone within the 2 weeks prior to the start of D2C7-IT infusion
8. Patients with worsening steroid myopathy (history of gradual progression of bilateral proximal muscle weakness, and atrophy of proximal muscle groups)
9. Patients with prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin
10. Patients with active autoimmune disease requiring systemic immunomodulatory treatment within the past 3 months
11. Patients who cannot undergo MRI due to obesity or to having certain metal in their bodies (i.e. pacemakers, infusion pumps, metal aneurysm clips, metal prostheses, joints, rods, or plates) or patients with any known severe allergies to contrast agents. Patients with mild allergies (i.e., rash only) are allowed to enroll and will be pretreated with acetaminophen and diphenhydramine prior to injection of the contrast agent.

Where this trial is running

Durham, North Carolina

• Duke University Medical Center — Durham, North Carolina, United States (Recruiting)

Study contacts

• Principal investigator: Daniel Landi, MD — Duke University
• Study coordinator: Daniel Landi, MD

Conditions Newly Diagnosed MGMT Unmethylated Glioblastoma; D2C7; D2C7-IT; 2141-V11; Pro00110119; GBM; Glioblastoma; convection-enhanced delivery